True Bearing Diagnostics has developed TruNAV, a novel RNA derived blood-based diagnostic test designed for the early detection of infections.
- TruNAV works by measuring specific RNA transcripts in whole blood that are associated with activation of the human immune system.
- TruNAV RNA transcript targets are highly sensitive to Neutrophil Activation by any pathogen, be it bacterial, viral, or biofilm based, and are unique in their ability to detect biofilm infections that cause appendicitis and other conditions.
- TruNAV has undergone multiple studies resulting in datasets, publications, and patents confirming scientific basis of the approach.
- TruNAV is poised to a multi-center FDA clinical study to confirm its utility with diagnosing the presence of internal infections in patients with abdominal pain.
- TruNAV provides the potential to also be useful with future pandemics or infections, like COVID19, because it can detect the presence of a pathogen even before it is fully identified, sequenced, and treatable.